Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,416
Views
8
CrossRef citations to date
0
Altmetric
Brief Report

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Brett A. Schroedera Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA;b Department of Medicine, Virginia Mason Medical Center, Seattle, WA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6019-2022
ORCID Icon,
Karan Kohlia Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA
,
Ryan B. O’Malleyc Department of Radiology, University of Washington, Seattle, WA, USA
,
Theresa S. Kima Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA
,
Robin L. Jonesd Sarcoma Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK
,
Robert H. Piercea Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA
&
Seth M. Pollacka Clinical Research Division, Fred Hutchison Cancer Research Center, Seattle, WA, USA;e Department of Medicine, University of Washington, Seattle, WA, USA
 show all
Article: 1710064 | Received 23 May 2019, Accepted 05 Dec 2019, Published online: 13 Jan 2020

Figures & data

Image 1. Contrast-enhanced CT images of the upper abdomen prior to initiating nivolumab (a, d) demonstrate low attenuation metastases within hepatic segments VI and II (arrows). Follow-up CT 2 years later (b, e) demonstrates that the metastasis in segment VI has decreased while the metastasis in segment II has completely resolved (arrows). Similarly, follow-up CT on 3/14/2018 (c, f) after cycle 64 of nivolumab demonstrates that the segment VI metastasis has again decreased and the segment II metastasis is still resolved (arrows)

Image 1. Contrast-enhanced CT images of the upper abdomen prior to initiating nivolumab (a, d) demonstrate low attenuation metastases within hepatic segments VI and II (arrows). Follow-up CT 2 years later (b, e) demonstrates that the metastasis in segment VI has decreased while the metastasis in segment II has completely resolved (arrows). Similarly, follow-up CT on 3/14/2018 (c, f) after cycle 64 of nivolumab demonstrates that the segment VI metastasis has again decreased and the segment II metastasis is still resolved (arrows)

Figure 1. (continued)

Figure 1. (continued)

Figure 1. Tumor tissue and tonsil (control) stained for CD3, CD4, CD163, PD-L1. Few CD3+, or CD4+ cells were detected in tumor. FOXP3 was detected in tumor, but not with CD3+ or CD4+ cells. Majority of myeloid tumor cells expressed PD-L1

Figure 1. Tumor tissue and tonsil (control) stained for CD3, CD4, CD163, PD-L1. Few CD3+, or CD4+ cells were detected in tumor. FOXP3 was detected in tumor, but not with CD3+ or CD4+ cells. Majority of myeloid tumor cells expressed PD-L1

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.